Once again the But-There's-Money-In-It apparatus has sprung to life to resuscitate hormone therapy (HT) in an article called The Estrogen Dilemma in this week's New York Times magazine.
For reporters and scientists aware of the cascade of hormone therapy (HT) cancer and morbidity studies, seeing its pharma-invented "benefits" disinterred for another lap around the track is like seeing an article suggesting cigarettes may be good for you after all.
Since the Women's Health Initiative (WHI) findings in 2002 -- which author Cynthia Gorney, parroting the pharma line, says overlooked younger women and cardio benefits --HT has been linked to asthma, lupus, scleroderma, non-Hodgkin's lymphoma, urinary incontinence, hearing loss, cataracts, malignant melanoma, lung cancer, gout, joint degeneration, dementia, loss of mental acuity, a shrinking brain, (pant, pant), diabetes complications and colon, ovarian, gall bladder and endometrial cancer.
And that's not counting the 26 percent increased risk of breast cancer, 29 percent increased risk of heart attack, 41 percent increased risk of stroke, and doubled risk of blood clots seen with the Women's Health Initiative.
(Note: You can view every article as one long page if you sign up as an Advocate Member, or higher).